PersImmune, Inc Report issue

For profit Phase 1
Founded: San Diego CA United States (2010)

Organization Overview

First Clinical Trial
2018
NCT03258359
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

PersImmune, Inc